MBRX Moleculin Biotech Inc: רווח למניה אחת ב-12 החודשים האחרונים

סמלים רשמיים של חברת Moleculin Biotech Inc (MBRX)

Moleculin Biotech, Inc. (MBRX) develops small molecules to combat aggressive cancer, leveraging high scientific credibility. R&D activities are accompanied by strict compliance with environmental regulations regarding chemical disposal. The current EPS YoY TTM trajectory, where the parameter equals 85.20, demonstrates the capitalization's resilience to Fed rates, which is critical for the success of anthracycline trials and patient survival rates.

Moleculin Biotech, Inc. (MBRX) - רווח נקי למניה (EPS TTM) מ-11.02.2024 עד 16.11.2026

Moleculin Biotech, Inc. - פילוחים אנליטיים ומדדי מפתח (MBRX)

- מחיר נוכחי ושווי מניות חזוי:
- נתוני שווי מניות החברה:
ניתוח ראשוני של החברה:MBRX, Moleculin
מוצרים מיוצרים של Moleculin

This indicator captures the dynamics of net income per share over a trailing twelve-month period, allowing for an assessment of the business's actual capitalization rate relative to previous periods. By analyzing the annual EPS TTM YoY trend, an investor can distinguish random market spikes from systemic growth, which is critically important for Moleculin Biotech, Inc. (MBRX) given its high capital burn rate and the toxicity risks associated with its oncology drug pipeline.